India, March 12 -- Aurobindo Pharma Limited on Thursday said that its wholly owned subsidiary has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its manufacturing facility in Andhra Pradesh.
According to the company, the inspection was conducted at Unit-IV of APL Healthcare Limited in Nellore district between December 8 and December 17, 2025.
As per the USFDA, a VAI classification indicates that certain objectionable conditions or practices were observed during the inspection, but they do not warrant administrative or regulatory action by the agency.
Published by HT Digital Content Services with permission from Dion Global Solut...